Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) saw a significant decrease in short interest during the month of June. As of June 15th, there was short interest totaling 367 shares, a decrease of 86.9% from the May 31st total of 2,801 shares. Based on an average daily volume of 4,811 shares, the days-to-cover ratio is presently 0.1 days.
Clinuvel Pharmaceuticals Stock Performance
Shares of Clinuvel Pharmaceuticals stock opened at $7.05 on Friday. Clinuvel Pharmaceuticals has a twelve month low of $5.98 and a twelve month high of $9.00. The business’s 50 day simple moving average is $6.73 and its 200-day simple moving average is $7.38.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Recommended Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
